<DOC>
	<DOCNO>NCT01509625</DOCNO>
	<brief_summary>This retrospective observational study design assess response treatment fulvestrant dose 500 mg/month load dose 500 mg ( LD-500 ) , term progression free survival ( PFS ) , overall survival ( OS ) , clinical benefit rate ( CBR ) , post-menopausal woman Advanced Breast Cancer estrogen receptor positive , treated medicinal product say dose progress previous anti-estrogen therapy . During study , retrospective data collection carry use information contain Clinical History say patient , provide treatment fulvestrant dose 500 mg LD-500 .</brief_summary>
	<brief_title>Retrospective Study Assessment Treatment Response Faslodex速 ( 500 mg )</brief_title>
	<detailed_description>Based result CONFIRM Study , centralise change dosage Faslodex速 500 mg/month , additional pre-loading dose 500 mg fourteen day treatment smart authorise Europe ; dose indicate treatment post-menopausal woman ABC , hormone receptor positive whose disease progress anti-estrogen therapy . Several site worldwide participate study , give importance result obtain impact , believe important local data available Spain would enable u determine new 500 mg dose Faslodex速 behave treatment assess treatment response within standard clinical practice current indication drug . Therefore , design retrospective , observational study measure response term PFS use data collect Clinical History . Likewise , variable study : OS , CBR , duration clinical benefit , tolerability safety . Patient subgroup , like over-express her-2 , accord level ki-67 presence visceral metastasis also study . This retrospective observational study design assess response treatment fulvestrant dose 500 mg/month load dose 500 mg ( LD-500 ) , term progression free survival ( PFS ) , overall survival ( OS ) , clinical benefit rate ( CBR ) , duration clinical benefit ( DCB , post-menopausal woman Advanced Breast Cancer estrogen receptor positive , treated medicinal product say dose progress previous anti-estrogen therapy . During study , retrospective data collection carry use information contain Clinical History say patient , provide treatment fulvestrant dose 500 mg LD-500 , occur point 1 January 2010 31 October 2011 ( hereinafter , study period ) . Thus , obtain PFS , OS CBR data , well information safety tolerability .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Signed Informed Consent patient possible . In event patient decease time inclusion , sign informed consent available ; thus , investigator assume responsibility data protection confidentiality safeguard processing data . Postmenopausal woman . Diagnosed locally advanced Metastatic Breast Cancer histological/cytological confirmation . Documented estrogen receptor positive status primary tumour . Patient , progression previous antiestrogen treatment , receive treatment time fulvestrant ( Faslodex速 ) 500 mg/month LD500 dose study period . Having receive treatment unapproved experimental drug study period . Presenting another concomitant cancer stage I cervical cancer cutaneous tumour without lymph node distant involvement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Fulvestrant</keyword>
	<keyword>Faslodex</keyword>
</DOC>